A POOLED ANALYSIS OF THE IMPACT OF AGE ON OUTCOMES IN PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE

被引：0
|
作者：
Palumbo, A. [1 ]
Dimopoulos, M. A. [2 ]
Richardson, P. G. [3 ]
Siegel, D. S. [4 ]
Cavo, M. [5 ]
Corradini, P. [6 ]
Weisel, K. C. [7 ]
Delforge, M. [8 ]
Chen, C. [9 ]
Goldschmidt, H. [10 ,11 ]
Jagannath, S. [12 ]
Lockhorst, H. M. [13 ]
Moreau, P. [14 ]
Plesner, T.
Sternas, L. [16 ]
Peluso, T. [15 ,17 ]
Hong, K. [16 ]
Herring, J. [16 ]
Yu, X. [16 ]
Zaki, M. H. [16 ]
San Miguel, J. [18 ]
机构：
[1] Univ Turino, Turin, Italy
[2] Univ Athens, Athens, Greece
[3] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA USA
[4] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[5] Univ Bologna, Sch Med, Seragnoli Inst Hematol, Bologna, Italy
[6] Univ Milan, Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[7] Univ Hosp Tuebingen, Tubingen, Germany
[8] Univ Hosp Leuven, Leuven, Belgium
[9] Princess Margaret Hosp, Toronto, ON, Canada
[10] Univ Hosp Heidelberg, Heidelberg, Germany
[11] German Canc Res Ctr, Heidelberg, Germany
[12] Mt Sinai Hosp, New York, NY 10029 USA
[13] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
[14] Univ Hosp Hotel Dieu, Nantes, France
[15] Univ Southern Denmark, Dept Hematol, Ctr Little Belt, Vejle Hosp, Vejle, Denmark
[16] Celgene Corp, Summit, NJ USA
[17] Celgene Int Sarl, Boudry, Switzerland
[18] Univ Navarra Clin, CIMA, IDISNA, Pamplona, Spain
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1295
引用
收藏
页码：535 / 536
页数：2
相关论文
共 50 条
  • [1] Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Richardson, Paul G.
    Siegel, David S.
    Cavo, Michele
    Corradini, Paolo
    Weisel, Katja
    Delforge, Michel
    O'Gorman, Peter
    Song, Kevin
    Chen, Christine
    Bahlis, Nizar
    Oriol, Albert
    Hansson, Markus
    Kaiser, Martin
    Anttila, Pekka
    Raymakers, Reinier
    Joao, Cristina
    Cook, Gordon
    Sternas, Lars
    Biyukov, Tsvetan
    Slaughter, Ana
    Hong, Kevin
    Herring, Jennifer
    Yu, Xin
    Zaki, Mohamed
    San-Miguel, Jesus
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 99 (03) : 199 - 206
  • [2] Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma
    Badros, Ashraf
    Hyjek, Elizabeth
    Ma, Ning
    Lesokhin, Alexander
    Dogan, Ahmet
    Rapoport, Aaron P.
    Kocoglu, Mehmet
    Lederer, Emily
    Philip, Sunita
    Milliron, Todd
    Dell, Cameron
    Goloubeva, Olga
    Singh, Zeba
    BLOOD, 2017, 130 (10) : 1189 - 1197
  • [3] OPTIMIZATION OF POMALIDOMIDE PLUS LOW DOSE DEXAMETHASONE IN REFRACTORY/RELAPSED MYELOMA MULTIPLE PATIENTS
    De Miguel, D.
    Gil, A.
    Golbano, N.
    Diaz, M.
    Guillen, H.
    Vazquez, A.
    Pinedo, B.
    HAEMATOLOGICA, 2017, 102 : 790 - 791
  • [4] MANAGEMENT OF ADVERSE EVENTS IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE: A POOLED SAFETY ANALYSIS OF 3 CLINICAL TRIALS
    Moreau, P.
    Dimopoulos, M. A.
    Richardson, P. G.
    Siegel, D.
    Palumbo, A.
    Cavo, M.
    Corradini, P.
    Weisel, K.
    Delforge, M.
    O'Gorman, P.
    Song, K.
    Sternas, L.
    Biyukov, T.
    Hong, K.
    Herring, J.
    Yu, X.
    Zaki, M. H.
    San Miguel, J.
    HAEMATOLOGICA, 2016, 101 : 531 - 531
  • [5] Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials
    Siegel, David S.
    Weisel, Katja C.
    Dimopoulos, Meletios A.
    Baz, Rachid
    Richardson, Paul
    Delforge, Michel
    Song, Kevin W.
    San Miguel, Jesus F.
    Moreau, Philippe
    Goldschmidt, Hartmut
    Cavo, Michele
    Jagannath, Sundar
    Yu, Xin
    Hong, Kevin
    Sternas, Lars
    Zaki, Mohamed
    Palumbo, Antonio
    LEUKEMIA & LYMPHOMA, 2016, 57 (12) : 2833 - 2838
  • [6] Selinexor Plus Pomalidomide and Low Dose Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma
    Chen, Christine I.
    Sutherland, Heather J.
    Kotb, Rami
    Sebag, Michael
    White, Darrell J.
    Bensinger, William
    Gasparetto, Cristina J.
    Leblanc, Richard
    Venner, Christopher P.
    Lentzsch, Suzanne
    Schiller, Gary J.
    Lipe, Brea
    Del Col, Aldo
    Shah, Jatin J.
    Jeha, Jacqueline
    Saint-Martin, Jean-Richard
    Kauffman, Michael G.
    Shacham, Sharon
    Bahlis, Nizar
    BLOOD, 2018, 132
  • [7] Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
    Dimopoulos, Meletios A.
    Weisel, Katja C.
    Song, Kevin W.
    Delforge, Michel
    Karlin, Lionel
    Goldschmidt, Hartmut
    Moreau, Philippe
    Banos, Anne
    Oriol, Albert
    Garderet, Laurent
    Cavo, Michele
    Ivanova, Valentina
    Alegre, Adrian
    Martinez-Lopez, Joaquin
    Chen, Christine
    Spencer, Andrew
    Knop, Stefan
    Bahlis, Nizar J.
    Renner, Christoph
    Yu, Xin
    Hong, Kevin
    Sternas, Lars
    Jacques, Christian
    Zaki, Mohamed H.
    San Miguel, Jesus F.
    HAEMATOLOGICA, 2015, 100 (10) : 1327 - 1333
  • [8] Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab
    Pierceall, William E.
    Bahlis, Nizar
    Siegel, David S.
    Schiller, Gary J.
    Samaras, Christy J.
    Sebag, Michael
    Berdeja, Jesus G.
    Ganguly, Siddhartha
    Matous, Jeffrey V.
    Song, Kevin
    Seet, Christopher S.
    Talamo, Giampaolo
    Srinivas, Shanti
    Acosta-Rivera, Mirelis
    Bar, Michael
    Quick, Donald P.
    Anz, Bertrand
    Fonseca, Gustavo
    Reece, Donna
    Chung, Weiyuan
    Serbina, Natalya
    Zafar, Faiza
    Agarwal, Amit
    Thakurta, Anjan
    BLOOD, 2018, 132
  • [9] IMPACT OF STABLE DISEASE AS A RESPONSE TO POMALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE ON SURVIVAL OUTCOMES IN PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA IN THE MM-003 TRIAL
    Moreau, P.
    Weisel, K.
    Song, K.
    Gibson, C.
    Saunders, O.
    Sternas, L.
    Hong, K.
    Zaki, K.
    Dimopoulos, M. A.
    HAEMATOLOGICA, 2015, 100 : 312 - 312
  • [10] Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure
    Siegel, David S.
    Schiller, Gary J.
    Song, Kevin W.
    Agajanian, Richy
    Stockerl-Goldstein, Keith
    Kaya, Hakan
    Sebag, Michael
    Samaras, Christy
    Malek, Ehsan
    Talamo, Giampaolo
    Seet, Christopher S.
    Mouro, Jorge
    Pierceall, William E.
    Zafar, Faiza
    Chung, Weiyuan
    Srinivasan, Shankar
    Agarwal, Amit
    Bahlis, Nizar J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (04) : 501 - 510
12345